TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Incidence of hepatitis during chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Duration of lamivudine use during chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patent infarct-related artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cumulative visual analog asthenopic symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in CST (Central Subfield Thickness)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in BCVA (Best Corrected Visual Acuity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of IOP elevation (Intraocular Pressure ≥24 mmHg)
Endpoint domain: Adverse events/effects
Primary endpoint: Effectiveness of multidisciplinary collaborative care
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in vasomotor symptom frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eating behaviour control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Geometric mean titers (GMTs) to diphtheria, tetanus, and pertussis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Protective titers against diphtheria and tetanus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Protective titers against PRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global cognitive function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Safety and tolerability of rosiglitazone
Endpoint domain: Adverse events/effects
Primary endpoint: Pain after the first defecation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in total lesion size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in total CNV size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in OCT centerpoint thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Short-term adverse effects per administration
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative times to standing, walking, passage of flatus and urinary catheter removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SCL-90 Index
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in the number of macrophages
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction in CD4+ T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction in CD8+ T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Device success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Residual stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: workplace absenteeism
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: improvement in global health
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: trait absorption scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Heart failure hospitalization (HHF) risk
Endpoint domain: Mortality/survival
Primary endpoint: pain intensity during the procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of S. mansoni infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: IL-10 responses to SWA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Odds ratios for deep vein thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: elevated depressive symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Classification performance score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Late fetal death
Endpoint domain: Mortality/survival
Primary endpoint: Lean body mass reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total number of polyethylene wear particles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean SB FFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Nutrient intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: New/newly enlarged T2 lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gadolinium-enhancing T1 lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean revised American Fertility Society scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of influenza-like illness
Endpoint domain: Adverse events/effects
Primary endpoint: Combined endpoint of death, CVA, or MI
Endpoint domain: Mortality/survival
Primary endpoint: number and severity of shoulder symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of fear of heights
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in mPASI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Dramatic responders (>70% response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in inflammatory acne lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Decrease in sebum secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Recurrent thrombosis
Endpoint domain: Mortality/survival
Primary endpoint: Major and minor bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: modified PPT score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FSQ score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Primary end point reached
Endpoint domain: Mortality/survival
Primary endpoint: Rate of SOR (Significant Outcome Reporting)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: mMRC scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Bowel colonization with resistant organisms
Endpoint domain: Adverse events/effects
Primary endpoint: Decrease in alanine aminotransferase (ALAT) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Improvement of plaque severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Active duodenal ulcer recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Cost-effectiveness of POC testing
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Time savings from POC testing
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence of mortality or abnormal neurological status at 40 weeks PMA
Endpoint domain: Mortality/survival
Primary endpoint: Survival free of neurodevelopmental impairment at 24‐30 months of chronological age
Endpoint domain: Mortality/survival
Primary endpoint: Change in serum PSA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive prostate biopsy results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Improvement of post-treatment symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in systemic cytokine responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction in DLQI score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in EASI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of gastric erosions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: activities of daily living (ADL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease improvement rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of questionnaire measures for depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum output in watt
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: METh/week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change in IOP from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Complete success rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Number of medications
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Target vessel revascularisation (TVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Risk of conversion from CIS to CDMS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with consent procedure
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Preference for consent procedure
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Use of tissue samples for medical research
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Clinical improvement in depression symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cumulative clinical success rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cumulative radiographic success rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical and radiographic survival probabilities
Endpoint domain: Mortality/survival
Primary endpoint: endoscopical scoring of turbinate size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nasal cavity volume and mean area at the level of the nasal valve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma levels of von Willebrand factor (vWF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: plasma levels of soluble P-selectin (sP-sel)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: periprosthetic infection rate
Endpoint domain: Adverse events/effects
Primary endpoint: Best-corrected visual acuity gain of greater than 3 lines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: POMS tension subscale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sensitivity of visual detection of diffuse multiple myeloma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of visual detection of diffuse multiple myeloma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of presentation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Quality of speaker
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Level of attention
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Area under the lithium serum concentration-time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean observed peak serum lithium concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to mean observed peak serum lithium concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total HF hospitalizations and cardiovascular death
Endpoint domain: Mortality/survival
Primary endpoint: simple fatigue scale
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: level of decisional conflict
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: shared decision making behaviors
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Patient perceptions of time spent
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Ashworth scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: percentage passive range of movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: subjective rating of problem severity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Frequency of cybersickness
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of cybersickness
Endpoint domain: Adverse events/effects
Primary endpoint: Urine IL‐6:Cr
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Osteoprotegerin/Cr
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body esteem shifts
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: ECG LVH as a predictor of worse prognosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Breastfeeding rates
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mechanical sensitivity of the vulvar vestibule
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean velocity (MV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak velocity (PV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean time under tension (TUT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma epicatechin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma theobromine concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: arterial stiffness (AIx)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: processing speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: fluid intelligence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Quality of life improvement as measured by SNOT-22
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Overall survival rate after 48 months
Endpoint domain: Mortality/survival
Primary endpoint: Dry weight reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neural activation in the dorsolateral prefrontal cortex (DLPFC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: detection ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in fasting and postprandial glucose concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change in insulin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change in C-peptide concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Restarted sinus rhythm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Left auricular volume reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Atrial enlargement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Efficacy and safety of early, intensive statin therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Role of low‐molecular‐weight heparin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in prolonged sitting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gastric mucosal visibility score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for water flushes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average and daily pain rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: suppression of dysesthetic pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: reduction of segmental reflexes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Tensile strength maintenance for wound healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Two-stage degradation of suture material
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: relative change in nausea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive impact from attending AA
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: myocardial salvage index (SI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Frequency of gastroesophageal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Response to PPV23 serotypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Response to TTV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Restoration of eubiosis in the small bowel lumen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Degree of BOS measured by hydrogen breath test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Normalization of the lactase test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: peak release of creatine kinase-MB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: peak release of troponin I
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: subjective improvement of the V-RQOL
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: improvement of fundamental frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement of voice intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of children with persistent diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: HbA1c reduction ≥1.0%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Weight loss ≥5.0%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: CD4+ T cell proliferation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: learning slope improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: objective measures of everyday memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sustained positive changes in attitudes, mood, and behavior
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Body fat percentage (%BF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urine specific gravity (USG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of severe disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: VAS pain score at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain medication use at 2 weeks postoperative
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Popeye deformity
Endpoint domain: Adverse events/effects
Primary endpoint: Overall food cravings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relative p‐cystatin C level changes from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Recurrence of aneurysms
Endpoint domain: Mortality/survival
Primary endpoint: DMFT and DMFS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak GH concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Area under the curve (AUC) GH concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: mean length-for-age z score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum SOFA scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LISs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transfusion risk
Endpoint domain: Adverse events/effects
Primary endpoint: Na(+) excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Abdominal postoperative pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Analgesic consumption for 24 h after surgery
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Improvement in peak FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes